ArticleCell division2026
The adipogenesis-related gene CEBPD as a prognostic biomarker and functional tumor suppressor in breast cancer.
Article in Cell division, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study explores the role of adipogenesis-related genes (ARGs) in breast cancer, focusing on CEBPD, a key gene linked to adipogenesis. Using the TCGA-BRCA dataset, differentially expressed ARGs (DARGs) were identified, revealing 26 upregulated and 57 downregulated genes. CEBPD emerged as a central prognostic gene, exhibiting significantly lower expression in tumor tissues, which correlated with poor survival outcomes, making it an independent prognostic indicator. A nomogram integrating CEBPD expression was developed to predict 1-year, 3-year, and 5-year survival with moderate accuracy. Functional validation in vitro confirmed that CEBPD expression was downregulated at mRNA levels in breast cancer. Enforced overexpression of CEBPD significantly suppressed cancer cell proliferation. Gene Set Variation Analysis (GSVA) highlighted significant associations between CEBPD and biological processes such as angiogenesis, apoptosis, hypoxia, and inflammation. Immune microenvironment analysis showed distinct patterns of immune cell infiltration based on CEBPD expression levels. Overall, CEBPD significantly influences breast cancer progression and patient prognosis, suggesting its potential as a biomarker for therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.